SLC5A2 and type 2 diabetes mellitus: Ertugliflozin (MK-8835/PF-04971729, SteglatroTM) is an orally active SGLT2 inhibitor being developed by Merck and Pfizer as a treatment for T2D (VERTIS MONO extension study) [64].